Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Sci. Aging Knowl. Environ., 29 October 2003
Vol. 2003, Issue 43, p. oa2
[DOI: 10.1126/sageke.2003.43.oa2]


Detangling Alzheimer's Disease

New insights into the biological bases of the most common cause of dementia are pointing to better diagnostics and possible therapeutics

Laura Helmuth;2003/43/oa2

Abstract: Alzheimer's disease afflicts 4.5 million people in the United States, and the number is expected to rise to 16 million by the year 2050, as the population ages. Researchers are scrambling to find genetic risk factors, decipher disease mechanisms, and develop reliable diagnostic tests that detect the illness at its earliest, potentially most treatable stage. Using these findings, they hope to devise new therapeutic approaches. Current clinical trials are assessing novel techniques that stall or reverse Alzheimer-like neuropathology in mice.

Citation: L. Helmuth, Detangling Alzheimer's Disease. Sci. SAGE KE 2003 (43), oa2 (2003).

Read the Full Text

Prototype Alzheimer's Disease Vaccine Using the Immunodominant B Cell Epitope from {beta}-Amyloid and Promiscuous T Cell Epitope Pan HLA DR-Binding Peptide.
M. G. Agadjanyan, A. Ghochikyan, I. Petrushina, V. Vasilevko, N. Movsesyan, M. Mkrtichyan, T. Saing, and D. H. Cribbs (2005)
J. Immunol. 174, 1580-1586
   Abstract »    Full Text »    PDF »

To Advertise     Find Products

Science of Aging Knowledge Environment. ISSN 1539-6150